FACT SHEET



IQVIA GrantPlan

Confidently forecast and budget investigator grants

Fast, accurate, efficient budgeting

Overcome the complexities of intricate protocols, large enrollment requirements, global site networks and delivery demands with IQVIA GrantPlan. Build more accurate study budgets while reducing costs and improving start-up times.

NEGOTIATE STREAMLINED, COMPLIANT INVESTIGATOR GRANTS

IQVIA GrantPlan simplifies the budgeting process, enabling life sciences companies and CROs to more efficiently, accurately and confidently build and adjust realistic clinical trial budgets and better negotiate investigator grants globally across all study phases and therapeutic areas.



MARKET LEADER FOR A REASON

This hosted, multi-tenant solution helps sponsors improve the site and investigator experience, while providing increased clarity and better oversight. The only cost tool to combine the most robust sources of data across the industry, GrantPlan provides fair market value (FMV) itemized costs that allow customers to more precisely budget across over 100 countries and 5,400 indications as they plan clinical trials.

UNPARALLELED ACCURACY & OPTIMIZED PERFORMANCE

Improved site experience Out-of-box deployment within days; built-in ondemand learning modules; live rep access

Greater efficiency Uses FMV line items for more accurate budgeting and greater cost savings More predictable study performance Combines the most robust data sources encompassing 5,400+ indications



Faster cycle times Make more strategic,

informed allocation decisions using latest data from 82K+ final budgets negotiated over last 2 years

Heightened accuracy

Compares to industry benchmarks and makes necessary adjustments; has visibility of previous final agreements of all global clinical trials use GrantPlan

Source: clinicaltrials.gov

DEFEND YOUR DECISIONS WITH THE MOST UP-TO-DATE DATA AVAILABLE

Continual information updating

Benchmarks are continuously expanded with blinded user data at the completion of each study. Data is refreshed quarterly.

Complete data availability

For price list, where actual data is insufficient, proprietary algorithms substitute benchmark costs which are updated annually. The client never sees a 0 in a line item. Supporting information is provided.


Unique U.S. Standard of Care module

Highlights charges already covered by patient insurance to avoid duplicate billing and save costs.

Power of Three and Five

Actuals come from at least 3 companies and at least 5 data points no more than 2 years old.

	etal (12247) Galdono Prospitulose, akaine (2077) (aeado) (aead	2 * 1 * 2 * 1 *	ther officer Unit Cest 72 21 24 34	Total 140 21 68 34 010249 85072 85072	Company Neal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Leve 61 23 20 20 20 00 60 247	Industry Bo Neal 73 21 24 24 249 73 249 73 321	1995 1995 1997 1997 209 209 209 209 209 209 209 209 209 209	008b 243 44 33 33 4977 1444 641		
nem (18 00) mile sakada (18 0	entition value de anti-	2 * 1 * 2 * 1 * 1 *	73 11 24 34	140 21 34 010249 05072 05072	0 0 0 0 0	51 13 23 307 60	73 21 24 34 249 72	87 23 33 44 317 92	143 44 33 53 497 144		
nem (18 00) mile sakada (18 0	antion % Albo: OH	2 v L v	21 34	68 34 030249 05072 05072	0000	20 20 307 60	24 34 249 73	33 44 317 92	93 33 497 144	l	
ended stages to be helione to be helione the stadened per statue (units constance) Salancy () () () () () () () () () (sh Alloc CH	L V	н	34 030249 05072 030324	0	23 207 60	34 349 72	++ 317 92	33 497 144	l	
Ng Har Andread Marson Madaland yang Pantana (1988) (tanàn ang Indonesia) Tanàna (tanàn ang Inggatang U.S. Carlor A.C.) In Dag Ng Yang	sh Alloc CH	6ekery	Pred	85072 880334		60	20	92	144		
offen keldered yn Politen (UMR Gowlaned) a Geferg) 🗮 Unned Statin 🖉 Germeny (Steprinting, U.S. Color S.C.C.) of Org. (Sta	sh Alloc CH	6ekery	Pred	010331							
n Solary 🐮 United States IN Connects (Support day U.S. Date 1992) IV Office of the States IN Connects (Support day U.S. Date 1992) IV Office Operation	sh Alloc CH	6ekery	iP rod			367	321	400	641		
Qity (pu	sh Alloc CH	6ekery	P rod								
Qity (pu	sh Alloc CH	6ekery	P rod								
Qty (mi	sh Alloc CH	6ekery	end .								
Qty (mi	sh Alloc CH	Selary			reporty		Industry Ba	ntheortes			
	eeths)		Total	to Alber	Net	Lane	Ned	tion	000		
r r		(Tearly) 330,137				293,406	229,127	290,068	435,633		
		100,110	91,791	0	0	203,424	339(137	790,044	405,401	<u></u>	_
ealBlonel Line Henry 📕 United States - Correctly Negatating - U.S. Collar (U\$65~)										(
	erfail a) (an. sention)		QFy 1	7			Hed				908h
72216 Magnetic resonance imaging, polvis, polvic (HR2): with contrast material(s) (eg	g, proton)		1		1,725	1,735	0	1,620	1.725	1.851	
14182 Magnetic resonance imaging, addimen, addominal (MR2), with contrast material Tumor imaging, positron emission tomography (24T) with concurrently acquire	fal(x) (xg. protox) of computed tomography	(CT) for attenuat	1			1,938					2,431
correction and anatomical localization; whole body; (CT Scan)						3.645		1,145	1,938	2,510	2,492
						2,645		3,409	1,938 3,645	2,510 3,856	2,492
81400° GARS (plys)t think synthetized) (ep. Charoot Harle Tooth disease).Ault pare sec 54	gueros		59		1,094	54,790			1,938 3,645 1,054	2,510 3,854 5,527	2,492
Salaw GARS (gyryl thisk syntheses) (eg. Charoot Harle Tooth disess)/All game sec		Lew 0363.636			1.094 Ma	54,790 d		3,409 1,870	1,938 2,646 1,054 Hig	2,510 3,854 5,537	2,492
		Low 0262,636			1,094	54,790 d		3,409 1,870	1,938 3,646 1,054 Hig 160373,63	2,510 3,854 5,537	2,492
Talat Benchmark Protecci Activities Subtatal Per Site					1.094 Ma	54,790 d	0	3,409 1,870 1999 Office USDS	1,028 3,646 1,054 Hig USD373,63 Hig USD373,63 Hig USD373,63	2,510 3,854 5,537	2,492
Tatel Sexchmark Protectel Activities Substat Per Site 1112 (Juli Time Enginyun) Buchtat Per Site					1.094 Ma	54,790 d	0	3,409 3,409 3,409 1107 offer USD397,3	1,038 2,646 1,054 Hig US0373,83 wd 63 09	2,510 3,854 5,537	2,492
Tend Benchmann Producel Activities Statistical Por Site 1111 (Call Time Engineeria) Individual Por Site Por Vision Processional For Statistical Por Site					1.094 Ma	54,790 d	0	3,409 1,870 1997 64% USD397,3 USD397,3	1,038 3,646 1,054 Hig US0373,83 Hid 63 09 68	2,510 3,854 5,537	2,492
Tatal Beschwark Pedical Activities Solited for Sta 1711 (1741 Tiss Engleycy) Bulleton for Mar Per Steep Terssnell are Solitetal for Mar Pers Theory Cachi Solitetal for Mar					1.094 Ma	54,790 d	0	3,409 1,870 1899 Ceffin USD37,3 USD37,4 USD3,4	1,038 3,646 1,054 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,83 Hig USD373,84 Hig USD374,84 Hig USD374,84 Hig USD374,84 Hig USD374,84 Hig USD374,84 Hig USD374,84 Hig USD374 Hig USD374,84 H	2,510 3,854 5,537	2,492
Tataf Bendenark Protocot Adrillinos Saddard Prv Sta TTC (14 Tatas Ranjunya) Subitata Prv Sta Prv Store Provinsed Fest Malanta Prv Sta Prv Storep Costo Subitata Prv Sta Stor Casto Subitata Prv Sta					1.094 Ma	54,790 d	•	3,400 1,870 1989 Celler USD397,3 USD3,4 USD3,4 USD3,4	1,038 3,645 1,054 1,055 1,056	2,510 3,854 5,537	2,492
Tatal Beschwark Pedical Activities Solited for Sta 1711 (1741 Tiss Engleycy) Bulleton for Mar Per Steep Terssnell are Solitetal for Mar Pers Theory Cachi Solitetal for Mar					1.094 Ma	54,790 d	5	3,409 1,870 1899 Ceffin USD37,3 USD37,4 USD3,4	1,038 2,645 1,054 1,054 1,054 1,054 1,054 1,054 0,050 1,054 0,050 0,00000000	2,510 3,854 5,537	2,492
	Veterical Athleties Cells Genzalptice 7351 Regards resonance mapping, chest, therea, theread (242) with convert mak- 7358 regards resonance mapping, parks, petro, (242), with convert material (2) regards, theread a second mapping and theread a second material regards, particle materials, submard (242), which converter scales resonance materials particles materials thereageable (247) with second-math- materials converters and antimicro thereageable (247) with second-math- second-math and antimicro thereadean votes table (252) (253)	Code: Developine 1935: Register assessment heading, check bares, horseld (HKE), with control multival(s) (og, protein) 1936: Register assessment heading, public, pelicit, pelicit, public, pelicit, public,	votacet Authities Code Description 71551 Regards resonance imaging, (hest, thoras, thorast; (HE)) with convair materia(s) (rap, proton) 7256 Magnetic resonance imaging, paint, paint; (HE), with convair materia(s) (rap, proton)	Vedecard Activities Celes Description Opport Statistics Opport Sta	Ventorial Justifies Op/ Op/	Vesterial Architeles The Objects Operation Operation Operation Operation Operation Operation I A 2,221 17/16 Wagnet research meding, deat, filteras, Nervisi (MIC) and constant medins(c) (op, protein) I e 2,221 72/16 Wagnet research meding, below, filteras, Nervisi (MIC) and constant medins(c) (op, protein) I e 2,221 72/16 Wagnet research meding, below, filteras, meding (MIC) and medine medine(c) (op, protein) I e 2,231	Deck Detailability Terr default Terr default Cash Detailability Op Edit Terr default 17.013<	Open Internation Performance Performance Description Open International Internationa Internatintereeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee	Vestorial Autholities Text Onlinear Company Image: Company Entry Onlinear Entry Onlinear Company Entry Onlinear Entry Onlin	Valued Jubilities Tate Onlinesi Company TableDay Set Code Second/plase Opy Opt Second Second Head Keet Head 30/31 Rayed in secondar market (1982) Secondar market (1982) </td <td>Veterical Activities Tater Officient Company Endestry Reschenzifies Code: Description Opy Cole: Mark Conet: Total of Mark I. Ma</td>	Veterical Activities Tater Officient Company Endestry Reschenzifies Code: Description Opy Cole: Mark Conet: Total of Mark I. Ma



Outsourcing enrollment model validation

Sponsors can run budgets through GrantPlan for evidence-based knowledge of what they should expect to see from CROs. Improves transparency and governance.

GRANTPLAN INVESTIGATOR-INITIATED STUDY (GPI) TOOLS

While investigator-initiated studies (IIS) have very specific needs, frequently they are not well met. GPI is the only tool built specifically for IIS. It allows users to forecast and evaluate FMV to assess and determine IIS budgets.

- Includes additional sections and line items accounting for FTE and per hour personnel fees
- Codes broken down by specialty and number of years' experience using in-application calculations.
- Can enter percent allocation and duration for each FTE and system calculates appropriate budget.

For more information on how GrantPlan can improve your clinical trials' probability of success, please contact us today to speak with an expert: orchestrateyourtrials@iqvia.com

